CompletedPhase 2NCT04010968
Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia
Studying B-cell chronic lymphocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- French Innovative Leukemia Organisation
- Principal Investigator
- Anne-Sophie MICHALLETCentre Leon Berard
- Intervention
- venetoclax and ibrutinib (I+VEN)(drug)
- Enrollment
- 120 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2025
Study locations (30)
- CH Annecy Genevois - Hématologie A3, Annecy, France
- Ch Cote Basque, Bayonne, France
- CH BLOIS, Blois, France
- Hôpital Avicenne - Centre de Recherche Clinique, Bobigny, France
- Institut Bergonie, Bordeaux, France
- CHU Caen - IHBN - Hématologie Clinique, Caen, France
- Hôpital Privé Sévigné, Cesson-Sévigné, France
- CHU Estaing - Hématologie Clinique Adulte, Clermont-Ferrand, France
- Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France
- Chu Creteil, Créteil, France
- GRENOBLE GHM - Institut Daniel Hollard, Grenoble, France
- CHU Grenoble - Hématologie, Grenoble, France
- CHD Vendée, La Roche-sur-Yon, France
- Centre Hospitalier du Mans, Le Mans, France
- Hôpital Saint Vincent de Paul, Lille, France
- +15 more locations on ClinicalTrials.gov
Collaborators
AbbVie · Janssen-Cilag Ltd.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04010968 on ClinicalTrials.govOther trials for B-cell chronic lymphocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07194980Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaFred Hutchinson Cancer Center
- RECRUITINGEARLY PHASE1NCT07428707Immune Profiling of CLL/SLL Treated With First-Line PirtobrutinibNational Heart, Lung, and Blood Institute (NHLBI)
- RECRUITINGPHASE4NCT07218341A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaEli Lilly and Company
- RECRUITINGPHASE1NCT06859008Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin LymphomaCity of Hope Medical Center
- RECRUITINGPHASE2NCT07271667A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell MalignanciesCuris, Inc.
- RECRUITINGPHASE2NCT07014917Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLLZulfa Omer
- RECRUITINGPHASE2NCT06958705Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor MonotherapyThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE1, PHASE2NCT07052695Mosunetuzumab for CLL MRD ClearanceInhye Ahn